Researchers found in a retrospective study of 297 surgically excised keloids with superficial radiation therapy around the excision site that only 3% recurred during an average 6-month follow-up. Read the full article here.
Blog
Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare’s SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities
Data from this Non-Invasive, Highly Effective Treatment Option for Non-Melanoma Skin Cancer Published in Journal of Drugs in Dermatology BOCA RATON, Fla., Feb. 12, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), announces the […]
Sensus Healthcare to Host Fourth Quarter and Full Year 2018 Financial Results and Business Update Conference Call on February 14, 2019
BOCA RATON, Fla., Jan. 30, 2019 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, February 14, 2019 at 4:30 p.m. Eastern time to discuss the financial results […]
The Florida Sun – Orlando Surgeon Who Removes Keloids Is The First In Nation To Use The Latest Technology
Dr. Kenrick Spence, a Central Florida doctor, discusses the benefits of the SRT-100+ for keloid removal at Hilcrest Plastic Surgery in Orlando. With over 18 million people suffering from keloids, the market to remove the painful and itchy overgrowths of scars is highly in demand in this community. Read the full article here.
MedicalResearch.com – Dermatologist (Dr. Kristine A. Romine, MD) Discusses Personalized Approach to Skin Cancer Treatment
Dr. Kristine A. Romine, MD, CEO and Founder of Camelback Dermatology & Skin Surgery in Phoenix, AZ, explains the difference the personalized approach to skin cancer treatment that SRT provides to skin cancer patients. Read the full article here.
Sensus Healthcare Announces Low 3% Keloid Recurrence in Multicenter Case Series of 297 Patients Treated with Superficial Radio Therapy
SRT-100, a Low-energy X-ray Technology, Used at Site of Keloidectomy Treatment BOCA RATON, Fla., Dec. 6, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), announced today positive results of a multicenter case series of […]
Alternative Skin Cancer Treatments with SRT
It is very important to offer alternative skin cancer treatments within your practice. The difference between having to go under the knife or not to have skin cancer removed can make a very big difference in the life of a patient. This is especially true for the elderly patient that sometimes has to go through […]
Sensus Healthcare Installs First Groundbreaking SRT-100+ Superficial Radio Therapy System for Treating Keloid Scars
Dr. Kenrick Spence of Hillcrest Plastic Surgery in Orlando First to Offer System BOCA RATON, Fla., Nov. 29, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), has installed its first SRT-100+ system at Hillcrest […]
8th Annual “New Frontiers in Cosmetic Medicine” (NFCM) Symposium
Join Sensus Healthcare at our Superficial Radio Therapy session taking place during the upcoming New Frontiers in Cosmetic Medicine (NFCM) Symposium on Sunday, November 18th. For more information click here, or to register click here.
Sensus Healthcare Third Quarter Financial Results Feature Revenue Growth of 32%
Shipped 18 systems during the quarter including 15 SRT-100 Vision™ systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 1, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results […]
Sensus Healthcare to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 1, 2018
BOCA RATON, Fla., Oct. 22, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, November 1, 2018 at 4:30 p.m. Eastern time to discuss the financial results […]
Dermatology Times – As an add-on to Mohs surgery, this treatment may have its benefits
Superficial Radio Therapy and our CEO, Joe Sardano, are making headlines with Dermatology Times. This article highlights the benefits of using SRT alongside Mohs surgery when treating skin cancer patients. With 80 percent of skin cancers appearing on the face and neck, a less invasive approach is very sought out by sufferers. Read the full […]
Physician Spotlight – January 2019
Dr. Steven K. Grekin, D.O. is the founder and Medical Director of The Grekin Skin Institute, a dermatological practice providing care within many segments of the medical market in Michigan. His primary mission is to help his patients put their best face forward by delivering extraordinary care and medical treatment. Having completed his undergraduate studies […]
Sensus Healthcare Brings Groundbreaking SRT-100 Vision System to Israel’s Largest Hospital for Skin Cancer and Keloid Treatment
SRT-100 Vision Coming to Patients at Sheba Medical Center Near Tel Aviv BOCA RATON, Fla., Oct. 17, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today announced that the Company has shipped its third […]
South Florida Business Journal Recognizes Sensus Healthcare’s Chief Technology Officer at 2018 Technology Awards
BOCA RATON, Fla., Oct. 16, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today announced that the South Florida Business Journal has recognized the Company’s Chief Technology Officer, Kal Fishman, as a finalist at […]
Top Reasons to Visit Sensus Healthcare at ASTRO
ASTRO’s Annual Meeting is the premier radiation oncology scientific event in the world and draws more than 11,000 attendees each year. This scientific program is the ideal platform to bring together physicians, scientists and researchers from all oncology disciplines to exchange ideas, promote multidisciplinary care and address the educational and professional development interests of attendees. […]
The Dermatologist – Empowering the Patient: Educating Patients on Different Skin Cancer Treatments
It is crucial for dermatologists to be at the frontline of the skin cancer epidemic. Jeffrey S. Fromowitz, MD, FAAD, understands the difficulty educating patients and providing physicians with the different skin cancer treatments that currently are available. Surgery is typically coupled with downtime and invasive procedures. Since many skin cancer treatment recipients are seniors, the […]
The Importance of Protecting Your Skin this Fall
As summer comes to an end, the weather gets cooler and the days grow shorter, leaving many people to store their sunscreen for the upcoming season. However, even in the fall months, ultraviolet (UV) protection is important in protecting your skin. In fact, UVA rays—which make up 95% of all UV rays—are almost as equally […]
2018 Aesthetic Awards: Non-Physician Non-Surgical Innovator of the Year Award
Over the past several years, Mr. Sardano, CEO of Sensus Healthcare, has worked tirelessly to offer a non-surgical solution for non-melanoma skin cancer and an effective treatment for keloid scars. The state-of-the-art Superficial Radio Therapy (SRT) technology is the non-surgical treatment option dermatologists and oncologists have been waiting for. Upon receiving the “Non-Physician Non-Surgical Innovator of […]
Sensus Healthcare, Inc. Announces Underwriters’ Exercise of Option
BOCA RATON, Fla., Sept. 21, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it has issued an additional 330,882 shares of its common stock pursuant to the exercise in full of the underwriters’ option received in connection with Sensus’ recently completed public offering of its common stock. After giving effect to the full […]